Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiago Torres

Showing results (241-250 of 274) with videos related to

Pageof 28
Sort By:
The World Allergy Organization Journal|August 11, 2023
Impact of asthma in Europe: A comparison of web search data in 21 European countriesHannah Wecker, Linda Tizek, Stefanie Ziehfreund, et al.
Journal of the American Academy of Dermatology|May 31, 2022
Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice settingAlejandra Reolid, Susana Armesto, Antonio Sahuquillo-Torralba, et al.
International Journal of Dermatology|July 18, 2025
Real-World Effectiveness, Safety and Drug Survival of Tildrakizumab in Adult Patients With Plaque Psoriasis: A 2-Year Portuguese Multicenter Retrospective Cohort StudyTiago Torres, Barbara Vieira Granja, Rita Guedes, et al.
Psoriasis (Auckland, N.Z.)|July 4, 2025
Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International ExperienceCristina Bertoli, Tiago Torres, Paolo Romita, et al.
Dermatology and Therapy|July 22, 2024
Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese StudyTiago Torres, Maria João Cruz, Margarida Gonçalo, et al.
Journal of the American Academy of Dermatology|February 22, 2019
Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective studyTiago Torres, Anna Balato, Curdin Conrad, et al.
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
The Journal of Dermatological Treatment|September 27, 2019
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world studyAndrea Chiricozzi, Anna Balato, Curdin Conrad, et al.
Acta Medica Portuguesa|January 7, 2023
Epidemiology of Psoriasis in Portugal: A Population-Based StudyTiago Torres, Paulo Filipe, Francisco Menezes Brandão, et al.
BMJ Open|July 11, 2025
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocolMatthias Augustin, Anthony Bewley, Marie-Charlotte Brüggen, et al.
Pageof 28

Showing results (241-250 of 274) with videos related to

Sort By:
Pageof 28
The World Allergy Organization Journal|August 11, 2023
Impact of asthma in Europe: A comparison of web search data in 21 European countriesHannah Wecker, Linda Tizek, Stefanie Ziehfreund, et al.
Journal of the American Academy of Dermatology|May 31, 2022
Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice settingAlejandra Reolid, Susana Armesto, Antonio Sahuquillo-Torralba, et al.
International Journal of Dermatology|July 18, 2025
Real-World Effectiveness, Safety and Drug Survival of Tildrakizumab in Adult Patients With Plaque Psoriasis: A 2-Year Portuguese Multicenter Retrospective Cohort StudyTiago Torres, Barbara Vieira Granja, Rita Guedes, et al.
Psoriasis (Auckland, N.Z.)|July 4, 2025
Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International ExperienceCristina Bertoli, Tiago Torres, Paolo Romita, et al.
Dermatology and Therapy|July 22, 2024
Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese StudyTiago Torres, Maria João Cruz, Margarida Gonçalo, et al.
Journal of the American Academy of Dermatology|February 22, 2019
Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective studyTiago Torres, Anna Balato, Curdin Conrad, et al.
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
The Journal of Dermatological Treatment|September 27, 2019
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world studyAndrea Chiricozzi, Anna Balato, Curdin Conrad, et al.
Acta Medica Portuguesa|January 7, 2023
Epidemiology of Psoriasis in Portugal: A Population-Based StudyTiago Torres, Paulo Filipe, Francisco Menezes Brandão, et al.
BMJ Open|July 11, 2025
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocolMatthias Augustin, Anthony Bewley, Marie-Charlotte Brüggen, et al.
Pageof 28